Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,829 Shares of Stock

Posted by Francis Steltz on Jul 7th, 2026

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) EVP Brenton Taylor sold 2,829 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $5.42, for a total value of $15,333.18. Following the completion of the sale, the executive vice president directly owned 264,978 shares of the company’s stock, valued at $1,436,180.76. The trade was a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sight Sciences Trading Down 0.5%

NASDAQ:SGHT traded down $0.03 during trading hours on Tuesday, hitting $5.42. The company had a trading volume of 5,954 shares, compared to its average volume of 280,934. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.86 and a quick ratio of 5.48. The stock has a 50-day moving average price of $4.95 and a 200 day moving average price of $5.31. The company has a market capitalization of $295.17 million, a PE ratio of -7.66 and a beta of 2.38. Sight Sciences, Inc. has a 52 week low of $3.11 and a 52 week high of $9.24.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). The company had revenue of $19.70 million during the quarter, compared to the consensus estimate of $18.46 million. Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%. On average, equities research analysts predict that Sight Sciences, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SGHT. Weiss Ratings cut Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Citigroup raised their target price on Sight Sciences from $4.35 to $5.15 and gave the company a “neutral” rating in a research note on Thursday, May 28th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Sight Sciences has a consensus rating of “Hold” and a consensus price target of $8.14.

View Our Latest Stock Analysis on Sight Sciences

Institutional Investors Weigh In On Sight Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its holdings in shares of Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after purchasing an additional 3,785 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in Sight Sciences during the fourth quarter valued at $81,000. AXQ Capital LP purchased a new stake in shares of Sight Sciences in the fourth quarter worth $89,000. Tower Research Capital LLC TRC increased its holdings in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after acquiring an additional 2,875 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Sight Sciences in the 4th quarter worth about $96,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

Negative Sentiment: CEO Paul Badawi sold 28,684 shares, trimming his stake by about 0.47%, in the largest disclosed insider transaction. Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock
Negative Sentiment: CFO James Rodberg sold 6,902 shares, reducing his ownership by nearly 3%, adding to the selling pressure from senior leadership. Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares
Negative Sentiment: CTO David Badawi sold 7,418 shares, while insider Jeremy B. Hayden sold 12,733 shares, reinforcing the pattern of insider reductions. Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $40,873.18 in Stock Sight Sciences (NASDAQ:SGHT) Insider Sells 12,733 Shares of Stock
Negative Sentiment: EVP Brenton Taylor also sold shares, continuing the broad pattern of insider selling across multiple executives. Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.